Biogen Idec Shifting Tysabri Sales Force To Avonex Detail
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen Idec will shift the focus of its Tysabri sales force to Avonex promotion following the marketing suspension of the newer multiple sclerosis agent, the company said
You may also be interested in...
Tysabri Study Participants To Undergo MRI, Physical In Search For Cause Of Adverse Events
Biogen Idec and Elan are suspending Tysabri clinical trials and conducting MRIs and physicals on trial participants as part of their voluntary marketing suspension of the multiple sclerosis therapy, the companies said
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.
Tysabri Study Participants To Undergo MRI, Physical In Search For Cause Of Adverse Events
Biogen Idec and Elan are suspending Tysabri clinical trials and conducting MRIs and physicals on trial participants as part of their voluntary marketing suspension of the multiple sclerosis therapy, the companies said